Search results for "Journal Article"

showing 10 items of 187 documents

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

2016

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care p…

PediatricsAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis; Immunology and AllergyIMPACTHay feverRespiratory Medicine and AllergyDiseaseReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineQUALITY-OF-LIFEHDE ALERHealth careMedicine and Health SciencesPERSISTENT ALLERGIC RHINITISMedicineImmunology and Allergy030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyAIRWAYS ICPComputingMilieux_MISCELLANEOUSRhinitiAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; RhinitisLungmedicin och allergiRhinitisPublic Health Global Health Social Medicine and Epidemiology3. Good healthREAL-LIFEAIRWAYS ICPsARIA; Rhinitis; ICT; EIP on AHA; Mobile technology; AIRWAYS ICPsHay feverCLINICAL-PRACTICE GUIDELINESHEALTHPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAEUROPEAN INNOVATION PARTNERSHIPImmunologySocio-culturaleClinical decision support systemICT; EIP on AHAPredictive medicine03 medical and health sciencesQuality of life (healthcare)Mobile technologyJournal ArticleMobile technologyAsmaAsthmaScience & TechnologyARIAbusiness.industryAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis;Settore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSCorrectionmedicine.disease2008 UPDATEFebre del fencAsthmaFolkhälsovetenskap global hälsa socialmedicin och epidemiologi030228 respiratory systemFamily medicineICTVISUAL ANALOG SCALEbusiness
researchProduct

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling…

2017

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 201…

Pediatricsddc:616.07medicine.disease_cause0302 clinical medicineCost of IllnessEpidemiologyPrevalenceEPIDEMIOLOGY030212 general & internal medicineSettore SECS-P/01 - Economia PoliticaCIRRHOSISmedia_commonddc:616Antiviral Agents/therapeutic useeducation.field_of_studyINJECT DRUGSGastroenterologyHCV INFECTIONvirus diseasesHepatitis CEmigration and ImmigrationDISEASE BURDENHepatitis CMarkov ChainsEmigration and Immigration/statistics & numerical data030211 gastroenterology & hepatologyViral hepatitisModelling ; Eradication ; European Union ; Hepatitis C ; prevalenceCOUNTRIESmedicine.medical_specialtyHepatitis C virusPopulationUNITED-STATESWorld Health OrganizationAntiviral Agents03 medical and health sciencesSDG 3 - Good Health and Well-beingPEOPLEInternal medicineIntervention (counseling)medicineJournal Articlemedia_common.cataloged_instanceHumansEuropean UnionViremiaEuropean unionDisease EradicationeducationHepatitis C/diagnosis/drug therapy/epidemiology/prevention & controlHepatologybusiness.industryViremia/diagnosis/drug therapy/epidemiology/prevention & controlHepatologymedicine.diseaseVirologyPREVENTIONdigestive system diseasesHuman medicineVIRAL-HEPATITISbusinessLancet Gastroenterology & Hepatology
researchProduct

Editorial [ Neurodegenerative Disorders: From Molecules to Man (Part 2) Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito ]

2008

NEURODEGENERATIVE DISORDERS: FROM MOLECULES TO MAN

PharmacologyPARKINSON'S DOPAMINEbusiness.industryGeneral NeuroscienceMEDLINEMedicinebusinessBioinformaticsSettore BIO/09 - FisiologiaIntroductory Journal ArticleCNS & Neurological Disorders - Drug Targets
researchProduct

Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Syndrome)

2014

Pharmacologymedicine.medical_specialtyEndocrinologybusiness.industryInternal medicineDrug DiscoverymedicineMEDLINEMetabolic syndromeIntensive care medicinemedicine.diseasebusinessIntroductory Journal ArticleCurrent Pharmaceutical Design
researchProduct

Editorial (Thematic Issue: Anderson Fabry Disease: A Multiorgan Metabolic Disease Susceptible of Treatment)

2013

Pharmacologymedicine.medical_specialtyPathologyAnderson-Fabry Diseasebusiness.industryDrug DiscoveryMEDLINEMedicineMetabolic diseasebusinessIntensive care medicineIntroductory Journal ArticleCurrent Pharmaceutical Design
researchProduct

From Polymers to Functional Biomaterials.

2017

Polymers and PlasticsChemistryPolymersMEDLINEBioengineeringBiocompatible Materials02 engineering and technologyComputational biology010402 general chemistry021001 nanoscience & nanotechnology01 natural sciencesModels Biological0104 chemical sciencesBiomaterialsDrug Delivery SystemsMaterials ChemistryAnimalsHumansNanoparticlesRNA Interference0210 nano-technologyBiotechnologyIntroductory Journal ArticleMacromolecular bioscience
researchProduct

Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICP…

2016

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adu…

Pulmonary and Respiratory MedicineGerontologyAllergen immunotherapymedicine.medical_specialtyAllergyAl·lèrgiaEIP on AHAAllergy[SDV]Life Sciences [q-bio]ImmunologyAlternative medicineImmunoteràpiaReview03 medical and health sciences0302 clinical medicinemedicineJournal ArticleImmunology and Allergy030212 general & internal medicineAsthmaAllergen immunotherapyRhinitisbusiness.industryPrecision medicinemedicine.diseaseAsthma3. Good healthIntegrated care[SDV] Life Sciences [q-bio]AgeingAIRWAYS ICPs030228 respiratory systemGeneral partnershipAction planImmunologyImmunotherapybusiness
researchProduct

Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe.

2017

While there is evidence for variations in prevalence rates of childhood wheeze and asthma between countries, longitudinal, individual-level data are needed to understand these differences. The aim of this study was to examine variations in prevalence rates of childhood asthma, wheeze and wheeze with asthma in Europe. We analysed datasets from 10 MeDALL (Mechanisms of the Development of ALLergy) cohorts in eight countries, representing 26 663 children, to calculate prevalence rates of wheeze and asthma by child age and wheeze with asthma at age 4 years. Harmonised variables included outcomes parent-reported wheeze and parent-reported doctor-diagnosed asthma, and covariates maternal education…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergy5Child age12Prevalencelcsh:MedicineChildhood asthma03 medical and health sciences0302 clinical medicineimmune system diseasesWheezeJournal Articlemedicine030212 general & internal medicineSleep medicineAsthmaChildhood asthmaAsthma and allergybusiness.industrylcsh:ROriginal Articlesmedicine.disease3. Good healthrespiratory tract diseasesMaternal educationCOPD and smoking030228 respiratory systemmedicine.symptombusinessDemography
researchProduct

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B…

2016

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organizatio…

Pulmons -- Malalties obstructivesVeterinary medicineAllergyPublished ErratumLANGUEDOC-ROUSSILLONAllergyRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Aparell respiratori -- MalaltiesOPERATIONAL DEFINITIONAlternative medicineReviewChronic respiratory diseasesGLOBAL ALLIANCESYSTEMS MEDICINE0302 clinical medicineMedicine and Health SciencesImmunology and AllergyMACVIA030212 general & internal medicineAIRWAYS ICPLungmedicin och allergiEIP on AHA; European Innovation Partnership on Active and Healthy Ageing; Chronic respiratory diseases; AIRWAYS ICPs; MACVIA; ARIA; Scaling upGINA STRATEGYAIRWAYSUPDATE ARIA 2008Scaling upRespiratory disease:Outras Ciências Agrárias [Ciências Agrárias]3. Good healthChronic respiratory diseaseALLERGIC RHINITISICPsAIRWAYS ICPsGeneral partnershipAction planErratumLife Sciences & BiomedicineAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling upPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling up; Immunology and AllergyEmerging technologiesImmunologyREFERENCE SITESocio-culturalePredictive medicine03 medical and health sciencesEuropean Innovation Partnership on Active and Healthy AgeingNursingCritical success factorJournal Articlemedicineddc:610Science & TechnologyARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSmedicine.diseaseIntegrated careAlliance030228 respiratory systemCiências Agrárias::Outras Ciências Agrárias3121 General medicine internal medicine and other clinical medicineFamily medicineImmunologyHealthy ageingbusinessSEVERE ASTHMA
researchProduct

The mechanism of aquaporin inhibition by gold compounds elucidated by biophysical and computational methods

2017

The inhibition of water and glycerol permeation via human aquaglyceroporin-3 (AQP3) by gold(iii) complexes has been studied by stopped-flow spectroscopy and, for the first time, its mechanism has been described using molecular dynamics (MD), combined with density functional theory (DFT) and electrochemical studies. The obtained MD results showed that the most effective gold-based inhibitor, anchored to Cys40 in AQP3, is able to induce shrinkage of pores preventing glycerol and water permeation. Moreover, the good correlation between the affinity of the Au(iii) complex to Cys binding and AQP3 inhibition effects was highlighted, while no influence of the different oxidative character of the c…

Surfaces Coatings and FilmAquaporinCeramics and CompositeOxidative phosphorylationMolecular Dynamics Simulation010402 general chemistryElectrochemistry01 natural sciencesCatalysisCatalysiMolecular dynamicschemistry.chemical_compoundGold CompoundsJournal ArticleMaterials ChemistryGlycerolHumansOrganic chemistryAquaporin 3Molecular Structure010405 organic chemistryChemistryElectronic Optical and Magnetic MaterialChemistry (all)Metals and AlloysGeneral ChemistryPermeation0104 chemical sciencesSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsSettore CHIM/03 - Chimica Generale E InorganicaCeramics and CompositesBiophysicsQuantum TheoryDensity functional theoryOrganogold CompoundsChemical Communications
researchProduct